Chirag Shah, MD
Pulmonary Disease · Bronx, NYNPI 1164629770
Payments from drug & device makers
Across 30 payments — averaging $205.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Bioventus LLC$182
- BD$164
- Galvanize Therapeutics, Inc$163
- Pulmonx Corporation$113
- Pacira Pharmaceuticals Incorporated$92
- plus $81 from 3 others
What the payments were for
- Speaking & faculty fees$5008%
- Travel & lodging$95215%
- Food & beverage$1,70928%
- Education$3,00049%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 19 | $5,367 |
| Bioventus LLC | 1 | $182 |
| BD | 2 | $164 |
| Galvanize Therapeutics, Inc | 2 | $163 |
| Pulmonx Corporation | 1 | $113 |
| Pacira Pharmaceuticals Incorporated | 1 | $92 |
| Novartis | 2 | $43 |
| Bristol Myers Squibb | 1 | $21 |
| Ambu Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$1,941
- Stimrouter Implantable Kit$182
- ALIYA SYSTEM$136
- Pulmonx Endobronchial Valve EBV$113
How this compares
$6,161 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $109,719 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $31,533 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $26,701 |
| Incruse ElliptaUmeclidinium Bromide | 66 | $22,516 |
| Arnuity ElliptaFluticasone Furoate | 44 | $12,234 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 166 | $6,484 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,141 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $3,925 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $3,905 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $3,471 |
| Roflumilast | 21 | $2,410 |
| Ventolin HfaAlbuterol Sulfate | 15 | $803 |
| Fluticasone Propionate | 56 | $398 |
| Azelastine Hcl | 21 | $256 |
| Prednisone | 103 | $193 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Bronx
- Samuel DeleonBronx$1.6M
- Raji AyinlaBronx$692K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.